Effects of Bazedoxifene Alone and with Conjugated Equine Estrogens on Coronary and Peripheral Artery Atherosclerosis in Postmenopausal Monkeys

Overview

Journal Menopause

Specialty Gynecology & Obstetrics

Date 2013 Feb 26

PMID 23435024

Citations 6

Authors

Thomas B Clarkson

Kelly F Ethun

Haiying Chen

Debbie Golden

Edison Floyd

Susan E Appt

Affiliations

Soon will be listed here.

Abstract

Objective: The objectives of this study were to evaluate the effects of bazedoxifene acetate (BZA), a new selective estrogen receptor modulator, on coronary and peripheral artery atheroscleroses and to determine if it would antagonize the atheroprotective effects of conjugated equine estrogens (CEE) on a monkey model.

Methods: Ninety-eight surgically postmenopausal monkeys (Macaca fascicularis) were fed a moderately atherogenic diet and randomized to receive no treatment or women's equivalent doses of BZA (20 mg/d), CEE (0.45 mg/d), or BZA + CEE. The experimental period lasted for 20 months (equivalent to approximately 5 y in humans) during which interim measures of cardiovascular risk factors were made. At the end of the experimental period, the extent and severity of coronary and iliac artery atheroscleroses were quantified.

Results: Body weight, adiposity, fasting glucose concentrations, and plasma lipid profiles were not different among treatment conditions. BZA had no adverse effects on the extent or severity of coronary or common iliac artery atherosclerosis when compared with no treatment. CEE, administered soon after inducing menopause, had robust atheroprotective effects on both the extent and the severity of iliac and coronary artery atheroscleroses. The addition of BZA to CEE treatment antagonized the atheroprotective effects of CEE.

Conclusions: In this nonhuman primate trial, treatment with BZA alone, CEE alone, and combined BZA and CEE does not have significant effects on plasma lipid profiles. CEE markedly inhibits the progression and complications of both coronary and iliac artery atheroscleroses. BZA has no adverse effects on atherosclerosis but attenuates the atheroprotective effects of CEE.

Citing Articles

Metabolic and morphometric changes in Indonesian cynomolgus monkeys (Macaca fascicularis) fed an atherogenic diet composed of locally sourced ingredients.

Laila S, Astuti D, Suparto I, Handharyani E, Sajuthi D Vet World. 2018; 11(11):1609-1617.

PMID: 30587897 PMC: 6303492. DOI: 10.14202/vetworld.2018.1609-1617.

The Tissue-Selective Estrogen Complex: A Review of Current Evidence.

Pazhekattu R, Lau A, Adachi J Rheumatol Ther. 2016; 2(1):47-58.

PMID: 27747497 PMC: 4883253. DOI: 10.1007/s40744-015-0013-z.

Infinium monkeys: Infinium 450K array for the Cynomolgus macaque (Macaca fascicularis).

Ong M, Tan P, MacIsaac J, Mah S, Buschdorf J, Cheong C G3 (Bethesda). 2014; 4(7):1227-34.

PMID: 24815017 PMC: 4455772. DOI: 10.1534/g3.114.010967.

Effects of equol on gene expression in female cynomolgus monkey iliac arteries.

Eyster K, Appt S, Chalpe A, Register T, Clarkson T Nutr Metab Cardiovasc Dis. 2014; 24(4):423-7.

PMID: 24525253 PMC: 3972297. DOI: 10.1016/j.numecd.2013.09.014.

Effects of estradiol on transcriptional profiles in atherosclerotic iliac arteries in ovariectomized cynomolgus macaques.

Eyster K, Appt S, Chalpe A, Mark-Kappeler C, Register T, Clarkson T Menopause. 2013; 21(2):143-52.

PMID: 23760433 PMC: 3815488. DOI: 10.1097/GME.0b013e31829367c0.

References

Hersh A, Stefanick M, Stafford R . National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004; 291(1):47-53. DOI: 10.1001/jama.291.1.47. View

Cline J, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B . Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol. 1996; 174(1 Pt 1):93-100. DOI: 10.1016/s0002-9378(96)70379-4. View

Clarkson T, Anthony M, Wagner J . A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab. 2001; 86(11):5396-404. DOI: 10.1210/jcem.86.11.8021. View

Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar J . Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009; 63(4):329-35. DOI: 10.1016/j.maturitas.2009.06.006. View

Adams M, Register T, GOLDEN D, Wagner J, Williams J . Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17(1):217-21. DOI: 10.1161/01.atv.17.1.217. View

Anderson G, Limacher M, Assaf A, Bassford T, Beresford S, Black H . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-12. DOI: 10.1001/jama.291.14.1701. View

Palacios S . The future of the new selective estrogen receptor modulators. Menopause Int. 2007; 13(1):27-34. DOI: 10.1258/175404507780456791. View

Chlebowski R, Hendrix S, Langer R, Stefanick M, Gass M, Lane D . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289(24):3243-53. DOI: 10.1001/jama.289.24.3243. View

Clarkson T, Kaplan J, Shively C, Klein K . Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis. Br J Obstet Gynaecol. 1996; 103 Suppl 13:73-8; discussion 78-9. View

10.

Lobo R, Pinkerton J, Gass M, Dorin M, Ronkin S, Pickar J . Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009; 92(3):1025-1038. DOI: 10.1016/j.fertnstert.2009.03.113. View

11.

Ethun K, Wood C, Register T, Cline J, Appt S, Clarkson T . Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause. 2012; 19(11):1242-52. PMC: 3762946. DOI: 10.1097/GME.0b013e318252e46d. View

12.

Losordo D, Kearney M, Kim E, Jekanowski J, Isner J . Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation. 1994; 89(4):1501-10. DOI: 10.1161/01.cir.89.4.1501. View

13.

Appt S, Clarkson T, Lees C, Anthony M . Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas. 2006; 55(2):187-94. DOI: 10.1016/j.maturitas.2006.02.002. View

14.

Manson J, Allison M, Rossouw J, Carr J, Langer R, Hsia J . Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356(25):2591-602. DOI: 10.1056/NEJMoa071513. View

15.

Clarkson T . The new conundrum: do estrogens have any cardiovascular benefits?. Int J Fertil Womens Med. 2002; 47(2):61-8. View

16.

Karim R, Mack W, Lobo R, Hwang J, Liu C, Liu C . Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause. 2005; 12(4):366-73. DOI: 10.1097/01.GME.0000153934.76086.A4. View

17.

Clarkson T . Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. Fertil Steril. 1994; 62(6 Suppl 2):147S-151S. View

18.

Clarkson T, Anthony M, Jerome C . Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab. 1998; 83(3):721-6. DOI: 10.1210/jcem.83.3.4617. View

19.

Bachmann G, Bobula J, Mirkin S . Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2009; 13(2):132-40. DOI: 10.3109/13697130903305627. View

20.

Williams J, Anthony M, Honore E, Herrington D, Morgan T, Register T . Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol. 1995; 15(7):827-36. DOI: 10.1161/01.atv.15.7.827. View